Clinical Trials Directory

Trials / Conditions / Progressive Multiple Sclerosis

Progressive Multiple Sclerosis

38 registered clinical trials studyying Progressive Multiple Sclerosis10 currently recruiting.

StatusTrialSponsorPhase
Not Yet RecruitingRESET-MS: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Multiple Sclerosis
NCT07006805
Cabaletta BioPhase 1 / Phase 2
RecruitingA Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therap
NCT07282574
Hoffmann-La RochePhase 2
RecruitingBringing the Outdoors In: Virtual Nature Walks for Depression in Multiple Sclerosis (MS) Patients
NCT07392879
University of MichiganN/A
RecruitingObe-cel in Refractory Progressive Forms of Multiple Sclerosis
NCT07139743
Autolus LimitedPhase 1
RecruitingOpen-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Followi
NCT06675864
Novartis PharmaceuticalsPhase 1 / Phase 2
Active Not RecruitingABA-101 in Participants With Progressive Multiple Sclerosis
NCT06566261
Abata TherapeuticsPhase 1
Not Yet RecruitingTelerehabilitation in Progressive Multiple Sclerosis
NCT06485115
Universita di VeronaN/A
Active Not RecruitingA Study of KYV-101, a CD19 CAR T Cell Therapy, in Participants With Treatment Refractory Progressive Multiple
NCT06451159
Bruce CreePhase 1
Enrolling By InvitationStudy of Circadian Focused Light Therapy in Progressive Multiple Sclerosis
NCT06261528
University of Texas Southwestern Medical CenterPhase 1
RecruitingEffects of Transcranial Static Magnetic Field Stimulation (tSMS) in Progressive Multiple Sclerosis
NCT05811013
Neuromed IRCCSN/A
RecruitingNicotinamide Riboside Supplementation In Progressive Multiple Sclerosis
NCT05740722
Haukeland University HospitalPhase 2
UnknownOsmotin Plant Protein for Progressive Multiple Sclerosis
NCT05937802
Ospedale Policlinico San MartinoN/A
Active Not RecruitingMasitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple S
NCT05441488
AB SciencePhase 3
Enrolling By InvitationVisual Processing Speed and Objective Analysis of Ocular Movements in Multiple Sclerosis
NCT05706220
Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA
UnknownMultiple Sclerosis Prediction and Monitoring of Progression Study
NCT05685784
University Hospital, GhentN/A
Active Not RecruitingStudy of Mesenchymal Autologous Stem Cells as Regenerative Treatment for Multiple Sclerosis
NCT04749667
Haukeland University HospitalPhase 1 / Phase 2
Active Not RecruitingChariotMS - Cladribine to Halt Deterioration in People With Advanced Multiple Sclerosis
NCT04695080
Queen Mary University of LondonPhase 2 / Phase 3
CompletedEffect of Variance on Error Correction During Coupling
NCT04856384
Hasselt UniversityN/A
CompletedIdentification of Retinal Perivascular Inflammation in Patients With Multiple Sclerosis Using Adaptive Optics
NCT04289909
Institut National de la Santé Et de la Recherche Médicale, FranceN/A
CompletedSerum Neurofilaments and GFAP in Atypical Multiple Sclerosis
NCT04201470
University Hospital, MontpellierN/A
CompletedEfficacy of Early Harvest Olive Oil in Cognition of Primary (PPMS) or Secondary (SPMS) Progressive Multiple Sc
NCT04120675
Aristotle University Of ThessalonikiN/A
CompletedA Trial of Bile Acid Supplementation in Patients With Multiple Sclerosis
NCT03423121
Johns Hopkins UniversityPhase 1 / Phase 2
CompletedComparing Tolerability and Absorption of Racemic and R-lipoic Acid in Progressive Multiple Sclerosis
NCT03493841
Rebecca SpainPhase 1
UnknownEvaluation of the Incidence of Relapses in Patients With Biotin-treated Progressive Multiple Sclerosis
NCT03552211
University Hospital, Clermont-Ferrand
CompletedNeural Stem Cell Transplantation in Multiple Sclerosis Patients
NCT03269071
IRCCS San RaffaelePhase 1
CompletedG-EO Gait Rehabilitation Training in Progressive Multiple Sclerosis
NCT03980145
Indiana UniversityN/A
CompletedA Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis
NCT02977533
SanofiPhase 1
CompletedA Study of Oxidative Pathways in MS Fatigue
NCT02804594
University of California, San FranciscoPhase 2
CompletedStudy to Assess Effect and Safety of High Dose of Biotin (Qizenday®) in Progressive Multiple Sclerosis
NCT03302806
Nantes University Hospital
CompletedA Study to Characterize Subcutaneous or Intravenous Alemtuzumab in Patients With Progressive Multiple Sclerosi
NCT02583594
Genzyme, a Sanofi CompanyPhase 1
CompletedAccess, Use and Opinions of Physiotherapy and Rehabilitation Services of People With Progressive MS in the UK.
NCT02559765
University of Glasgow
CompletedA Long-term Follow-up Study Of Multiple Sclerosis Patients Who Participated In Genzyme-sponsored Studies of GZ
NCT02313285
Genzyme, a Sanofi Company
CompletedA First-in-human, Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis
NCT02282826
Genzyme, a Sanofi CompanyPhase 1
TerminatedStudy by Magnetic Resonance Imaging in the Progressive Forms of Multiple Sclerosis
NCT02580669
University Hospital, MontpellierN/A
UnknownAssessment of Bone Marrow-derived Cellular Therapy in Progressive Multiple Sclerosis (ACTiMuS)
NCT01815632
North Bristol NHS TrustPhase 2
CompletedCyclic Oral Methylprednisolone Trial in Multiple Sclerosis
NCT01305837
Rigshospitalet, DenmarkPhase 2
UnknownSafety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Scl
NCT01364246
Shenzhen Beike Bio-Technology Co., Ltd.Phase 1 / Phase 2
CompletedIntrathecal Therapy With Monoclonal Antibodies in Progressive Multiple Sclerosis
NCT01719159
Anders SvenningssonPhase 2